US4515890A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunoassay of terminal deoxynucleotidyl transferase
Assignee: Abbott Laboratories
•
Filing: 1982-11-08
•
Granted: 1985-05-07
•
Expires: 2002-11-08
Abstract
Abstract This disclosure relates to a method for the quantitative in vitro determination of terminal deoxynucleotidyl transferase in human blood extracts, bone marrow extracts and lymphocyte extracts and wherein the terminal deoxynucleotidyl transferase is extracted with an extractant containing a nonionic surfactant, an anticoagulant and a reducing agent.
Inventors
- 👤 George L. Manderino
- 👤 Adoracion F. Suarez
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 08:00
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; Y; Y10; Y10S; Y10S435/00; Y10S435/961; Y10S435/963; Y10S436/00; Y10S436/811; Y10S436/813
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
132 words
A method for quantitatively determining terminal deoxynucleotidyl transferase (TdT) antigen in a sample comprising: (a) extracting the TdT antigen from the sample by treating the sample with an effective amount of an extractant composition comprising a nonionic surfactant, anticoagulant and a reducing agent which stabilizes TdT by preventing intermolecular disulfide bond formation of the TdT and preventing oxidation of TdT in a buffered medium; (b) contacting the extracted TdT antigen with a solid support coated with anti-TdT thereby forming an antigen-anti-TdT complex on the solid support; (c) treating the antigen-antibody complex on the solid support with a labeled anti-TdT antibody specific for TdT antigen to form an antibody-antigen-anti-TdT complex on the solid support; and (d) determining the amount of antibody-antigen-anti-TdT complex formed as a measure of TdT antigen present in the sample.
Claim 2
Independent Claim
132 words
A method for quantitatively determining terminal deoxynucleotidyl transferase (TdT) antigen in a sample comprising: (a) extracting the TdT antigen from the sample by treating the sample with an effective amount of an extractant composition comprising a nonionic surfactant, anticoagulant and a reducing agent which stabilizes TdT by preventing intermolecular disulfide bond formation of the TdT and preventing oxidation of TdT in a buffered medium; (b) contacting the extracted TdT antigen with a solid support coated with anti-TdT thereby forming an antigen-anti-TdT complex on the solid support; (c) treating the antigen-antibody complex on the solid support with a labeled anti-TdT antibody specific for TdT antigen to form an antibody-antigen-anti-TdT complex on the solid support; and (d) determining the amount of antibody-antigen-anti-TdT complex formed as a measure of TdT antigen present in the sample.
Claim 3
Dependent Claim
13 words
A method according to claim 1 wherein the anticoagulant is a chelating anticoagulant.
Claim 4
Dependent Claim
16 words
A method according to claim 2, wherein the chelating anticoagulant is ethylenediaminetetraacetic acid or salts thereof.
Claim 5
Dependent Claim
12 words
A method according to claim 1 wherein the reducing agent is glutathione.
Claim 6
Dependent Claim
12 words
A method according to claim 1 wherein the nonionic surfactant is TWEEN-20.
Claim 7
Dependent Claim
18 words
A method according to claim 1 wherein the extractant composition is buffered at a pH less than 7.
Claim 8
Dependent Claim
22 words
A method according to claim 6 wherein the extractant composition is buffered at a pH within a range of 5.5 to 6.5.
Claim 9
Dependent Claim
21 words
A method according to claim 7 wherein the extractant comprising TWEEN-20, ethylenediaminetetraacetic acid and glutathione in a phosphate buffered saline medium.
Claim 10
Independent Claim
17 words
A method as in any one of claims 1-8 wherein the anti-TdT is labeled with an enzyme.
Claim 11
Independent Claim
16 words
A method as in any one of claims 1-8 wherein the sample is a blood specimen.
References Cited (Backward Citations)
US3839153A
Cited
US3932141A
Cited
US4020151A
Cited
JPS56118671A
Cited
US4307189A
Cited
US4363634A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-06 | 1988-11-05 | 1989-05-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-06 | 1992-11-05 | 1993-05-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-06 | 1996-11-05 | 1997-05-07 | $7700.00 | Window Closed / Lapsed |